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Lentinus edodes is the medicinal macrofungus showing potential for therapeutic applications in infectious disorders including
hepatitis. In an attempt to develop the agent for handling hepatic injury, we used the extracts of Lentinus edodes mycelia (LEM)
to screen the eﬀect on hepatic injury in rats induced by carbon tetrachloride (CCl4). Intraperitoneal administration of CCl4 not
only increased plasma glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) but also decreased
hepatic superoxide dismutase (SOD) and glutathione peroxidase (GPx) levels in rats. Similar to the positive control silymarin,
oral administration (three times daily) of this product (LEM) for 8 weeks signiﬁcantly reduced plasma GOT and GPT. Also, the
activities of antioxidant enzymes of SOD and GPx were elevated by LEM. in liver from CCl4-treated rats, indicating that mycelium
can increase antioxidant-like activity. Moreover, the hepatic mRNA and protein levels of SOD and GPx were both markedly raised
by LEM. The obtained results suggest that oral administration of the extracts of Lentinus edodes mycelia (LEM) has the protective
eﬀect against CCl4-induced hepatic injury in rats, mainly due to an increase in antioxidant-like action.
1.Introduction
Hepatic injury may result from many risk factors, such as
hepatic virus, inﬂammation, and alcohol consumption [1–
3]. Oxidative stress is a state of redox imbalance resulted
from elevated reactive oxygen species (ROS) generation and
decreased antioxidant capacity [4]. In general, obesity is
believed as an important risk factor for liver injury in man
[5]. Carbon tetrachloride- (CCl4-) induced hepatic injury is
a well-established animal model due to generation of oxi-
dativestresstoresultinhepaticoxidativedamageandinﬂam-
mation [6]. Thus, CCl4-induced hepatic injury is a common
animal model widely used to evaluate the hepatoprotective
action of testing compounds [7–9].
Lentinus edodes is the medicinal macrofungus showing
potential for therapeutic applications in infectious disorders
including hepatitis [10]. The extract of Lentinus edodes
Mycelia (LEM) exhibits medicinal eﬀects such as anticancer
activity and immunoregulatory activity [11]. Protection
of LEM against liver damage induced by chemicals has
been documented such as dimethylnitrosamine [12]a n dD -
galactosamine[13].Bothreportswerecarriedoutincultured
hepatic cells. However, the eﬀect of LEM on hepatic injury
in animal remains unclear. Thus, we screen the extracts of
LEM in rats using CCl4-induced liver damage model while
silymarin is used as a positive control because it is popularly
applied as the protective substance in CCl4-induced hepatic
damage [14, 15]. The main aim of the present study is going
to clarify the role of antioxidant-like activity in the liver
protection of this product (LEM).
2.MaterialsandMethods
2.1. Materials. The LEM powder named as Shung-Kang
in Chinese was kindly supplied from Tsung Hsin Tsan
Company (Neihu Technology Research Institute, Taipei City,
Taiwan). It was prepared as previously reported [16]. Brieﬂy,
Lentinus edodes mycelia were cultivated in a solid medium2 The Scientiﬁc World Journal
composed of sugar-cane bagasse and defatted rice bran.
The medium with mycelia was incubated for digestion with
mycelial enzymes in water at 30–55◦C, and then the incu-
bation temperature was increased to 90◦C for inactivation
of the enzymes and sterilization. The digest was ﬁltered,
lyophilized, and used as the LEM preparation. Moreover, the
anti-rat SOD and GPx antibodies to measure hepatic SOD
andGPxproteinswerepurchasedfromBiodesign(Saco,ME,
USA). The plasma glutamic oxaloacetic transaminase (GOT)
and glutamic pyruvic transaminase (GPT) were measured by
assaykitsfromAppliedBio(Hercules,CA,USA).Inaddition,
theactivitiesofhepaticSODandGPxweredeterminedusing
the kits from Cayman Chemical Company, Inc. (Ann Arbor,
Michigan, USA). Silymarin alone or LEM alone did not alter
liver injury parameters by themselves (data not shown).
2.2. Experimental Animals. Male Wistar rats aged 8 weeks
were obtained from the Animal Center of National Cheng
Kung University Medical College. They were maintained in
a temperature-controlled room (25 ± 1◦C) and kept on
a 12:12 light-dark cycle (light on at 06:00h). Food and
water were available ad libitum. All animal procedures were
performed according to the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health as
well as the guidelines of the Animal Welfare Act.
2.3. Experimental Protocols
2.3.1. Chronic Administration of LEM in CCl4-Treated Rats.
The dried LEM powder was dissolved in saline solution
for oral administration at the desired doses. The hepatic
injury of rats was induced with CCl4 (1mL/kg, i.p.) dis-
solved in olive oil. In the present study, all experimental
rats were divided into six groups: (1) vehicle-treated Wistar
rats, (2) vehicle-treated CCl4-induced rats, (3) silymarin
(200mg/kg)-treated CCl4-induced rats, (4) LEM (100mg/
kg)-treated CCl4-induced rats, (5) LEM (200mg/kg)-treated
CCl4-induced rats, and (6) LEM (500mg/kg)-treated CCl4-
induced rats. In brief, CCl4-induced rats received an oral
administration of silymarin or LEM at the indicated dose
or the same volume of vehicle three times daily for 8 weeks.
Bloodsamples(1mL)ofthetreatedratswerecollectedunder
sodium pentobarbital anesthesia (30mg/kg, i.p.) from the
femoral vein at the indicated time point for measurement
of plasma glutamic oxaloacetic transaminase (GOT) and
glutamic pyruvic transaminase (GPT) using an autoanalyzer
(Quik-Lab, Ames, Miles Inc., Elkhart, Indiana, USA).
2.3.2. Determination of Mn-SOD and Cu/Zn-SOD Activities.
Rats were sacriﬁced under sodium pentobarbital anesthesia
(60mg/kg, i.p.). The liver was removed and we washed liver
tissues with saline to remove as much blood as possible.
Mn-SOD and Cu/Zn-SOD concentrations were determined
using commercially available rat assay kits from Cayman
Chemical Company, Inc. (Ann Arbor, MI, USA). Hepatic
samples were homogenized at 4◦Ci ni c e - c o l dh o m o g e n i z e d
buﬀer containing 0.32mol/L Sucrose, 1mmol/L EDTA, and
10nmol/L Tris-HCl, pH 7.4 in a Teﬂon/glass homogenizer.
The homogenate was centrifuged at 1400×gf o r5 m i na t
4◦C and the supernatant was centrifuged at 4500×gf o r
10min. Then, the supernatant was centrifuged at 11000×g
for 60min. We analyzed the supernatant to measure Cu/Zn-
SOD activity, and the pellet was used to measure Mn-SOD
activity. Then, we added 20μL of sample, 200μLo fr e a g e n t
solution, and 20μL of enzyme working solution to the wells
and mixed thoroughly. We incubated the plate at 37◦Cf o r
20min. The determination of Mn-SOD and Cu/Zn-SOD in
samples was carried out and the absorbance was measured
by a SPECTRAmax 340PC ELISA reader (Molecular Devices
Corporation, Union City, CA, USA) at 450nm. SOD activity
w a se x p r e s s e da sU / m gp r o t e i n .
2.3.3. Determination of GPx Activity. Rats were sacriﬁced
under sodium pentobarbital anesthesia (60mg/kg, i.p.). The
liver was removed and GPx concentration was determined
usingacommerciallyavailableassaykitfromCaymanChem-
ical Company, Inc. (Ann Arbor, Michigan, USA). Hepatic
samples were homogenized at 4◦C in ice-cold homogenized
buﬀercontaining50mmol/LTris-HCl,5mmol/LEDTA,and
1mmol/L DTT, pH 7.5 in a Teﬂon/glass homogenizer. The
homogenate was centrifuged at 10000×gf o r1 5m i na t4 ◦C
and the supernatant was used for GPx quantiﬁcation. Then,
we added 20μL of sample, 100μL of assay buﬀer and 50μL
cosubstrate mixture to the wells. To initiate the reactions,
we added 20μL of cumene hydroperoxide to the wells being
used and carefully shook the plate for a few seconds to mix.
The determination of GPx in samples was carried out and
the absorbance was measured by an SPECTRAmax 340PC
ELISA reader (Molecular Devices Corporation, Union City,
CA, USA) at 340nm. GPx activity was expressed as nmol
NADPH/min/mg protein.
2.3.4. Northern Blotting Analysis of mRNA Level. Northern
blotting analysis was obtained from four individual experi-
ments. Total RNA was extracted from the liver of all exper-
imental animals using the UltraspecTM-II RNA extraction
system. The concentration of RNA was measured using
the absorbance at 260nm. For Northern blotting analysis,
total RNA (40μg) was denatured in a solution containing
2.2mmol/L formaldehyde and 50% formamide (v/v) by
heating at 55◦C for 15min. Aliquots of total RNA were
then size-fractionated in a 1.2% agarose/formaldehyde gel.
Ethidium bromide staining was used to identify the position
of the 18S and 28S rRNA subunits and to conﬁrm that
equivalent amounts of undegraded RNA had been loaded.
The fractionated RNA was transferred to a hybond-N mem-
brane (Amersham Corp., Bucks, UK) and crosslinked by UV
irradiation (Stratagene, CA, USA). Probes were labeled with
[γ-32P] dCTP (New England Nuclear, Boston, USA) using
theMedaprimelabelingsystemkit(AmershamCorp.,Bucks,
UK). Hybridizations were carried out in medium containing
denatured salmon sperm DNA (100μg/mL) at 65◦Cf o r
2hrs. The membrane was washed twice for 20min in 2 ×
sodium saline citrate (SSC)/0.1% SDS at room temperature
and once for 20min in 0.1 × SSC/0.1% SDS at 40◦C.
Autoradiograms were prepared on Kodak X-ray (Rochester,The Scientiﬁc World Journal 3
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Figure 1: Eﬀect of LEM on hepatic injury in CCl4-treated rats. All rats were received oral administration at indicated dose three times per
day. (a) Normal rats treated with vehicle. (b) Normal rats treated with CCl4 f o r8w e e k s .( c )C C l 4-treated rats received oral administration of
silymarin (200mg/kg) for 8 weeks. (d) CCl4-treated rats received oral administration of LEM (100mg/kg) for 8 weeks. (e) CCl4-treated rats
received oral administration of LEM (200mg/kg) for 8 weeks. (f) CCl4-treated rats received oral administration of LEM (500mg/kg) for 8
weeks. Histology of liver was characterized by staining with hematoxylin-eosin (Magniﬁcation: ×400).
NY, USA) ﬁlm using a single enhancing screen at −80◦C.
Intensities of the mRNA bands on the blot were quantiﬁed
by scanning densitometry (Hoefer, San Francisco, CA, USA).
The response of β-actin was used as an internal standard.
2.3.5. Western Blotting Analysis of Protein Level. Western
blotting analysis was obtained from four individual exper-
iments. After homogenization of the liver from all exper-
imental rats using a glass/Teﬂon homogenizer, the homo-
genates (50μg) were separated by sodium dodecyl sulfate-
polyacrylamidegelelectrophoresis,andWesternblotanalysis
was performed using an anti-rat Mn-SOD antibody, Cu/Zn-
SOD antibody, and GPx antibody (1:1000) purchased from
Biodesign (Saco, ME, USA) in liver. The blots were probed
with a goat polyclonal actin antibody (1:500) from Zymed
Laboratories (South San Francisco, CA, USA) to ensure
that the amount of protein loaded into each lane of the gel
was constant. Blots were incubated with the appropriate
peroxidase-conjugated secondary antibodies. After removal
of the secondary antibodies, the blots were washed and
developed using the ECL-Western blotting system. Densities
of the obtained immunoblots at 25KDa for Mn-SOD,
16KDa for Cu/Zn-SOD, 24KDa for GPx, and 43KDa for
actin were quantiﬁed using laser densitometer.
2.3.6. Histological Analysis. The liver tissues were removed
from each group of rats and ﬁxed in 10% formaldehyde
at 4◦C for 2 days. Fixed specimens were dehydrated and4 The Scientiﬁc World Journal
embedded in paraﬃn. The specimens were then cut into
5μm thick sections at 50μm intervals and then stained
with hematoxylin and eosin (H&E; Muto Pure Chemicals,
Tokyo, Japan). The sections were then observed with a light
microscope.
2.3.7. Data Analysis. The results are expressed as the stan-
dard error of the mean (S.E.M.) from the number (n)o f
individual experiments performed. Statistical analysis was
performed by one-way ANOVA followed by Dunnett’s post
hoc test. A probability level of P value less than 0.05 was
required for statistical signiﬁcance.
3. Results
3.1. Eﬀect of LEM Administration on Liver Damage in CCl4-
Treated Rats. Rats treated by CCl4 signiﬁcantly induced
hepatic injury. As shown in Figure 1(b), inﬂammatory cells
were observed in CCl4-induced hepatic tissues. Oral admin-
istration of 200mg/kg silymarin for 8 weeks improved CCl4-
induced hepatic injury markedly (Figure 1(c)). In addition,
oral administration of LEM for 8 weeks also markedly
improved CCl4-induced hepatic injury in a dose-dependent
manner (Figures 1(d), 1(e),a n d1(f)).
3.2. Eﬀect of LEM on Plasma Glutamic Oxaloacetic Transami-
nase(GOT)andGlutamicPyruvicTransaminase(GPT)Levels
in CCl4-Treated Rats. As shown in Figure 2(a),C C l 4-treated
rats showed a higher plasma GOT level as compared with
vehicle-treated normal rats. Similar to the rats treated with
silymarin (200mg/kg) for 8 weeks as positive control, oral
administration of LEM into CCl4-treated rats three times
daily for 8 weeks signiﬁcantly lowered the plasma GOT level
(100mg/kg, 200mg/kg, and 500mg/kg). Same results were
also observed in plasma GPT levels as shown in Figure 2(b).
3.3. Eﬀect of LEM on the Activities of Hepatic Superoxide
Dismutase (SOD) and Glutathione Peroxidase (GPx) in CCl4-
Induced Rats. CCl4-treated rats showed lower levels of
both Mn-SOD and Cu/Zn-SOD in liver as compared with
vehicle-treatednormalrats.Oraladministrationofsilymarin
(200mg/kg) three times daily for 8 weeks produced a
signiﬁcant elevation in the activities of hepatic Mn-SOD and
Cu/Zn-SOD. Also, oral administration of LEM into CCl4-
treated rats in same manner resulted in an increase of Mn-
SOD and Cu/Zn-SOD activities in liver (Figures 3(a) and
3(b)). As shown in Figure 3(c),C C l 4-treated rats showed a
lower activity of GPx in liver than the vehicle-treated normal
rats. Similar to the eﬀect of silymarin (200mg/kg), oral
administration of LEM into CCl4-treated rats three times
daily for 8 weeks also produced an increase of GPx activity
in liver.
3.4. Eﬀects of LEM on Gene Expressions of Antioxidative
Enzymes in Liver of CCl4-Treated Rats. CCl4-treated rats
showed a decrease in mRNA levels of Mn-SOD, Cu/Zn-
SOD, and GPx in liver. Oral administration of LEM into
CCl4-treated rats three times daily for 8 weeks produced
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Figure 2: Eﬀect of LEM on plasma GOT and GPT levels in CCl4-
treated rats. (a) Changes of plasma GOT by oral administration
of LEM in CCl4-treated rats for 8 weeks. (b) Changes of plasma
GPT by oral administration of LEM in CCl4-treated rats for 8
weeks. Lane 1: vehicle-treated Wistar rats; lane 2: vehicle-treated
CCl4-induced rats; lane 3: silymarin- (200mg/kg) treated CCl4-
induced rats; lane 4: LEM- (100mg/kg) treated CCl4-induced rats;
lane 5: LEM- (200mg/kg) treated CCl4-induced rats; lane 6: LEM-
(500mg/kg) treated CCl4-induced rats. Data represent mean ±
SEM of eight animals. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001
compared with CCl4-induced group receiving vehicle.
an elevation in mRNA levels of Mn-SOD, Cu/Zn-SOD, and
GPx in liver (Figure 4(a)). Western blotting analysis also
showed a similar reduction on the protein levels of Mn-SOD,
Cu/Zn-SOD, and GPx in liver of CCl4-treated rats. Similarly,
elevation in protein levels of Mn-SOD, Cu/Zn-SOD, and
GPx was produced by LEM in a dose-dependent manner
(Figure 4(b)). The data for quantiﬁcation of Mn-SOD,
Cu/Zn-SOD, and GPx mRNA values were shown in Table 1.
Also, the data for quantiﬁcation of Mn-SOD, Cu/Zn-SOD,
and GPx protein values were presented in Table 2.
4. Discussion
In the present study, we found that the extracts of Lentinus
edodes mycelia (LEM) can signiﬁcantly lower plasma GOT
and GPT in CCl4-treated rats. Also, histological change of
liver induced by CCl4 was improved by treatment with
LEM for 8 weeks. Moreover, LEM. signiﬁcantly increasedThe Scientiﬁc World Journal 5
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Figure 3: Eﬀects of LEM on activities of hepatic Mn-SOD, Cu/Zn-SOD, and glutathione peroxidase (GPx) in CCl4-treated rats. (a)
Changes of hepatic Mn-SOD by oral administration of LEM in CCl4-treated rats for 8 weeks. (b) Changes of hepatic Cu/Zn-SOD by oral
administration of LEM in CCl4-treated rats for 8 weeks. (c) Changes of hepatic GPx by oral administration of LEM in CCl4-treated rats for
8 weeks. Lane 1: vehicle-treated Wistar rats; lane 2: vehicle-treated CCl4-induced rats; lane 3: silymarin- (200mg/kg) treated CCl4-induced
rats; lane 4: LEM- (100mg/kg) treated CCl4-induced rats; lane 5: LEM- (200mg/kg) treated CCl4-induced rats; lane 6: LEM- (500mg/kg)
treated CCl4-induced rats. Data represent mean ± SEM of eight animals. ∗P<0.05 and ∗∗P<0.01 compared with CCl4-induced group
receiving vehicle.
the activities of hepatic Mn-SOD, Cu/Zn-SOD, and GPx
after 8 weeks of treatment. Therefore, improvement of CCl4-
induced hepatic injury by LEM seems to be related to an
increase in antioxidant-like activities.
Plasma GOT and GPT levels are reliable makers for the
evaluation of hepatic injury. CCl4-induced hepatic injury
showed a marked increase in plasma GOT and GPT levels
as described previously [17, 18]. Also, as shown in Figure 1,
histological change of liver was observed in rats that received
CCl4 showing the success of this animal model. Similar to
previous reports [19, 20], silymarin signiﬁcantly decreased
theplasmaGOTandGPTlevelsinCCl4-treatedrats.Inaddi-
tion, LEM also lowered the plasma GOT and GPT levels in
CCl4-treatedratsandimprovedthehepaticinjury(Figure 1).
The protective eﬀect of LEM against CCl4-induced liver
damagecanthusbeconsideredinrats.Thisisconsistentwith
the previous reports using dimethylnitrosamine [12]o rD -
galactosamine [13].
Hepatic injury induced by CCl4 was associated with
oxidative stress due to CCl4-induced free radical production
[21, 22]. In addition, inﬂammatory cytokines TNF-α and
IL-6 were also involved in this hepatic injury while the
antioxidative compound (resveratrol) can protect hepatic
injury by suppressing oxidative stress [23]. Thus, we focused
on the change of oxidative stress in this action of LEM.
In general, superoxide dismutase (SOD) is an important
antioxidant enzyme which catalyzes the conversion of toxic
superoxide radical to less reactive hydrogen peroxide [24].
SOD is known to be reduced markedly in CCl4-induced hep-
atic injury [25] while oxidative stress could be ameliorated
via the elevation of hepatic SOD level [26]. In addition,
glutathione peroxidase (GPx) is another antioxidant enzyme
commonly used to investigate the oxidative stress [27]. It
hasbeenindicatedthatantioxidant-likecompoundsproduce
hepatic protection through an increase in GPx to scavenge
the free radicals [28, 29]. In the present study, LEM increased
the activities of Mn-SOD, Cu/Zn-SOD, and GPx in liver
of CCl4-treated rats (Figure 3). Similar results were also
observed in gene expressions of these enzymes using Western
blotting analysis for protein level or Northern blotting
analysis for mRNA level (Figure 4). Data of quantiﬁcation
show the markedly changes of gene expressions; both mRNA
level (Table 1)a n dp r o t e i nl e v e l( Table 2)i nl i v e ro fr a t s
received LEM against CCl4 in a way similar to silymarin.6 The Scientiﬁc World Journal
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Figure 4: Eﬀects of LEM on gene expressions of Mn-SOD, Cu/Zn-
SOD, and glutathione peroxidase (GPx) in liver of CCl4-treated
rats. (a) The representative picture showing mRNA levels for Mn-
SOD, Cu/Zn-SOD, GPx, or β-actin in liver isolated from CCl4-
induced rats receiving treatment with silymarin or LEM three
times daily for 8 weeks. Lane 1: vehicle-treated Wistar rats; lane
2: vehicle-treated CCl4-induced rats; lane 3: silymarin- (200mg/kg)
treated CCl4-induced rats; lane 4: LEM- (100mg/kg) treated CCl4-
induced rats; lane 5: LEM- (200mg/kg) treated CCl4-induced rats;
lane 6: LEM- (500mg/kg) treated CCl4-induced rats. (b) The
representative response of protein level for Mn-SOD, Cu/Zn-SOD,
G P x ,o ra c t i ni nl i v e ri s o l a t e df r o mC C l 4-induced rats receiving
treatment with silymarin or LEM three times daily for 8 weeks. All
lanes are expressed as the same as mRNA level (a) on the above.
Thus, increase of hepatic SOD and GPx levels is related to
the decrease of plasma GOT and GPT levels by LEM in rats
that received CCl4-induced hepatic injury.
The main components of LEM are sugars, proteins,
polysaccharides,andpolyphenoliccompounds.Thepolysac-
charides including lentinan, eritadenine, shiitake mushroom
mycelium, and culture media extracts (LEM, LAP, and KS-2)
are known to enhance immunity [10] while glycogen-like
polysaccharides have macrophage-activating activity [11].
Polyphenols are mentioned to produce protection against
cardiovascular disease and neurodegenerative disorders in
addition to cancers [30–32]. Among polyphenols, syringic
acid and vanillic acid are enriched in the solid medium of
Table 1: The quantiﬁcation of mRNA levels for Mn-SOD, Cu/Zn-
S O D ,G P x ,o rβ-actin in liver isolated from CCl4-induced rats
receiving treatment with silymarin or LEM three times daily for
8 weeks. Quantiﬁcation of mRNA levels using Mn-SOD/β-actin,
Cu/Zn-SOD/β-actin, and GPx/β- a c t i nw a se x p r e s s e da sm e a nw i t h
s t a n d a r de r r o r( S E )( n = 4 per group) in each group. ∗P<0.05
compared with CCl4-induced group receiving vehicle.
Mn-SOD
(arbitrary units)
mRNA/β-actin
Cu/Zn-SOD
(arbitrary units)
mRNA/β-actin
GPx
(arbitrary units)
mRNA/β-actin
Control 1.31 ±0.11∗ 1.20 ±0.08∗ 1.91 ±0.17∗
CCl4 0.69 ±0.06 0.75 ±0.05 1.03 ±0.08
+ Silymarin
200mg/kg 1.15 ±0.07∗ 1.37 ±0.07∗ 1.48 ±0.11∗
+L E M
100mg/kg 0.64 ±0.04 1.24 ±0.09∗ 1.50 ±0.18∗
200mg/kg 0.82 ±0.05∗ 1.37 ±0.11∗ 1.55 ±0.13∗
500mg/kg 1.09 ±0.08∗ 1.71 ±0.13∗ 2.10 ±0.15∗
Table 2: The quantiﬁcation of protein levels for Mn-SOD, Cu/Zn-
SOD, GPx, or actin in liver isolated from CCl4-induced rats
receiving treatment with silymarin or LEM three times daily for
8 weeks. Quantiﬁcation of protein levels using Mn-SOD/actin,
Cu/Zn-SOD/actin, and GPx/actin was expressed as mean with
s t a n d a r de r r o r( S E )( n = 4 per group) in each group. ∗P<0.05
compared with CCl4-induced group receiving vehicle.
Mn-SOD
(arbitrary units)
protein/actin
Cu/Zn-SOD
(arbitrary units)
protein/actin
GPx
(arbitrary units)
protein/actin
Control 1.24 ±0.07∗ 1.42 ±0.15∗ 1.18 ±0.08∗
CCl4 1.01 ±0.04 1.02 ±0.05 0.82 ±0.06
+ Silymarin
200mg/kg 1.16 ±0.05∗ 1.60 ±0.09∗ 1.11 ±0.05∗
+L E M
100mg/kg 0.82 ±0.06 0.91 ±0.04 1.06 ±0.05∗
200mg/kg 1.03 ±0.11 1.07 ±0.03 1.23 ±0.14∗
500mg/kg 1.21 ±0.10∗ 1.67 ±0.06∗ 1.59 ±0.17∗
cultured LEM [33]. L. edodes grown in lignocellulose secretes
lignin-degrading peroxidase into the culture medium [34].
The mycelia-derived enzymes degrade the lignin to produce
phenolic compounds, particularly syringic acid and vanillic
acid,whichareintroducedasactiveprinciplesforliveprotec-
tion of LEM [35]. However, more investigations are required
to make clear of the real substances for liver protection of
LEM in the future.
Basically, LEM is the popular edible mushroom in the
global market which is attributed to its nutritional value.
Thus, the safety of LEM has been conﬁrmed in clinics
[36] in addition to animals [37]. Also, LEM can improve
atherosclerosis [38] and produce many pharmacologicalThe Scientiﬁc World Journal 7
properties including the antibiotic, anticarcinogenic, and
antiviral actions from intracellular fraction (fruiting body
and mycelia) and extracellular fraction (culture media) as
described previously [10]. The potential of LEM is unques-
tionable as important one in the applications of medicinal
therapy.
In conclusion, from the obtained results, the present
study is the ﬁrst one that provided the evidence that oral
administration of the extracts from Lentinus edodes mycelia
(LEM) improves hepatic injury induced by CCl4 in Wistar
rats. The merits of LEM from antioxidant-like action which
is not mentioned before also make it to be a suitable agent
for the treatment of hepatic injury in the future.
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